Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01302626 |
| Other study ID # |
10-4-120 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
February 22, 2011 |
| Last updated |
March 21, 2017 |
| Start date |
March 2010 |
| Est. completion date |
March 2014 |
Study information
| Verified date |
March 2017 |
| Source |
Maastricht Radiation Oncology |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Aim of the study: The main aim is to collect data of patients with lung cancer, and to
perform different analyses on this data. The data contains information on patient and tumor
characteristics, imaging, and treatment characteristics. With this data it is possible to
improve and validate the predictive model for survival and long term toxicity in lung cancer
by multicentric prospective data collection. The long term aim, beyond this specific study,
is to build a Decision Support System based on the predictive models validated in this
study.
Hypothesis: The general hypothesis is that we get a better prediction in terms of AUC (area
under the curve) of survival and long term toxicity when we combine multifactorial
variables. These variables consist of information from clinical data, imaging data, data
related to treatment type and treatment quality.
Description:
1. Treatment of lung cancer
Lung cancer is the most common cause of cancer death in The Netherlands, with an annual
incidence exceeding 8,000. Two main variants of lung cancer can be identified: small
cell and non-small cell lung cancer (SCLC and NSCLC respectively), the latter
comprising approximately 80% of the lung cancer cases. Despite treatment improvement,
the prognosis of NSCLC remains poor, with a median survival of 8 months after
diagnosis, and a 5 year survival of less than 13%.
Radiotherapy plays a key role in the treatment of NSCLC. Over the years,
radiotherapeutical treatment options have increased tremendously. These include dose
escalation, more intensive schedules and concurrent chemo-radiotherapy. These schedules
have improved both local control and survival in patients. However, they also induce
more toxicity, and the radiation oncologist faces the challenging task of choosing the
optimal therapy for each patient: taking into account tumor characteristics as well as
the patient's condition. In other words: the physician must estimate the expected
therapeutic ratio often on a background of insufficient outcomes information.
The same problem arises in other therapies for lung cancer, chemotherapy and surgery.
In early disease, surgery is the mainstay of the treatment of lung cancer patients.
This can be combined with neoadjuvant or adjuvant chemotherapy and/or radiotherapy.
2. Prediction of response
A major problem in lung cancer management is the lack of data dealing with predictive
factors for prognosis and treatment outcome. The currently used staging system (TNM)
does not accurately predict outcome within homogeneous treatment groups. As a result,
an individualized therapeutic ratio cannot be calculated, leading to either over- or
under-treatment of many patients and hampering further optimization of any therapy.
Attempts were undertaken to refine and improve the risk stratification, leading to the
development of several prediction models. The performance of the models is usually
expressed as the Area Under the Curve (AUC) of the Receiver Operating Characteristic
(ROC). The maximum value of the AUC is 1.0; indicating a perfect prediction model. A
value of 0.5 indicates that patients are correctly classified in 50% of the cases, e.g.
as good as chance.
While high prediction accuracy (AUC=0.85) has been achieved for a population of NSCLC
patients of all stages, treated with different modalities, it is a more challenging
task to predict survival accurately when focusing on a subgroup. A pretreatment
prediction model for patients treated with surgery yielded an AUC of 0.61 while a
pretreatment model for patients treated with radiotherapy resulted in an AUC of 0.75.
Further improvement of the radiotherapy model was obtained by adding information about
blood biomarkers and this extended model yielded an AUC of 0.83. Investigating other
blood biomarkers or possible combinations of biomarkers is a challenge and our results
underline the importance of using these data in addition to clinical and imaging
parameters.
Survival remains certainly an outcome of major importance, but the last decades other
treatment-related outcome measures, such as radiation induced lung injury or esophageal
damage, became more important for the evaluation of treatment results.
Pneumonitis or radiation induced lung injury has been subject of many studies. However,
results are quite difficult to interpret, because many different variables, dosimetric
parameters as well as other treatment or patient related characteristics, have been
identified, studies showed inconsistent or even conflicting results, and sample sizes
were often very limited.
Recently, Chen et al. published a neural network model for prediction of grade 2 or
higher pneumonitis, which yielded an AUC of 0.74 in the test dataset31. Compared to
other models, these results are promising, although external validation of the model is
warranted before it can be used in clinical practice. Our group developed a model
predicting dyspnea ≥ grade 2 according to CTCv3.0. Patient as well as dosimetric
parameters were incorporated in the model, which resulted in a cross-validated AUC of
0.62.
In summary, existing models perform rather well, but there is a lot of room for
improvement by adding new factors as well as applying advanced model building
techniques. Prediction models still have to be developed for a number of clinically
relevant outcomes. Finally, incorporating confidence intervals in the prediction as
well as quantifying the gain in prediction precision if a certain diagnostic/
prognostic test is performed, would certainly be of great value for clinical use of the
models (http://www.predictcancer.org/).
3. Strategies to improve prediction models for lung cancer
In order to improve the prediction models for survival as well as toxicity outcome one can
include many variables as possible predictors including imaging, genomics and proteomics
information.
3.1 Imaging
An important feature for prognosis on the FDG-PET-scan is the maximal Standardized Uptake
Value (SUVmax). There is a statistically significant difference in 2-year survival between
patients with a high pretreatment SUV and a low pretreatment SUV. Patients with a low SUVmax
had a 2-year survival of 90.6%, while patients with a high SUVmax had a 2-year survival of
only 58.6%. There is a significant correlation between high SUVmax and a high HIF1α staining
in the biopsies, which is a marker for hypoxia. Non significant relations were shown for CA
IX, Ki67 and Glut-1 and SUVmax.
Besides FDG, new PET-tracers are being developed. One of the new tracers is HX4, which is a
hypoxia tracer. Regulation of tissue oxygen homeostasis is critical for cell function,
proliferation and survival. Evidence for this continues to accumulate along with our
understanding of the complex oxygen-sensing pathways present within cells. The
microenvironment of tumors in particular is very oxygen heterogeneous, with hypoxic areas,
which may explain much of our difficulty in treating cancer effectively. This is true when
comparing levels of hypoxia among different patient tumors, but also within individual
tumors. Accumulating evidence implicates the biological responses to hypoxia and the
alterations in these pathways in cancer as important contributors to overall malignancy and
treatment efficacy. This has recently prompted several investigations into the possibility
of imaging and targeting treatment at the biological responses to hypoxia.
3.2 Gene signatures
Analysis of gene signatures can help to improve the predictive value of the model. An
example of this, is the proliferation signature investigated by Starmans et al. Two
different signatures of 110 genes were compared in prognostic value. Both showed a very good
prognostic value on breast cancer data sets. The AUC (area under the curve) improved when
the proliferation signature were added to the models of clinical factors. Another gene
profile was tested on early stage NSCLC. This profile consists of 72 genes and is validated
on stage I and II NSCLC patients of five centers. It was possible to identify early-stage
NSCLC patients with high and low risk for disease recurrence and death within 3 years after
primary surgical treatment.
3.3 Tumor biopsies
Hypoxia is (besides in serum) also measurable in the tissue itself. Several markers of
hypoxia are predictive for survival. An example is HIF1α, which is upregulated is case of
hypoxia. A higher staining of HIF1α is correlated with a worse prognosis in NSCLC. CA IX
correlated with severe and chronic hypoxia, and has a strong association with a poor outcome
in NSCLC.
Another marker is Ki67, which is expressed in proliferating cells. A higher Ki67 indicates
more proliferation, and in a systemic review of Martin et. al. a worse prognosis was shown
when Ki67 expression is increased.
3.4 Application of machine learning techniques
The availability of genomic data, together with improved imaging modalities, leads to
unprecedented amounts of biological and medical data, which can only be dealt with using
computational methods, not only for storing the data, but also for integrating, analyzing,
displaying and eventually understanding it.
Machine learning offers a number of techniques for these purposes. These techniques can
overcome problems encountered with conventional statistical methods especially if data is
highly correlated, many variables are available but a limited number of patients
(high-dimensional data), or many different models have to be tested for their predictive
value. In the field of radiotherapy and especially for the prediction of treatment
responses, machine learning is an upcoming modality. Successes over traditional statistics
have already been published 43and first promising results for building predictive models
concerning survival of non-small-cell lung-cancer are already found in the literature.
